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Preamble and Transition to ACC/AHA
Guidelines to Reduce Cardiovascular Risk
The goals of the American College of Cardiology (ACC)
and the American Heart Association (AHA) are to prevent
cardiovascular diseases (CVDs); improve the management
of people who have these diseases through professional
education and research; and develop guidelines, standards,
and policies that promote optimal patient care and car-
diovascular health. Toward these objectives, the ACC and
AHA have collaborated with the National Heart, Lung,
and Blood Institute (NHLBI) and stakeholder and pro-
fessional organizations to develop clinical practice guide-
lines for assessment of cardiovascular risk, lifestyle
modiﬁcations to reduce cardiovascular risk, management of
blood cholesterol in adults, and management of overweight
and obesity in adults.
In 2008, the NHLBI initiated these guidelines by
sponsoring rigorous systematic evidence reviews for each
topic by expert panels convened to develop critical ques-
tions (CQs), interpret the evidence, and craft recommen-
dations. In response to the 2011 report from the Institute
of Medicine on the development of trustworthy clinical
guidelines (1), the NHLBI Advisory Council recom-
mended that the NHLBI focus speciﬁcally on reviewing
the highest-quality evidence and partner with other orga-
nizations to develop recommendations (2,3). Accordingly,
in June 2013 the NHLBI initiated collaboration with
the ACC and AHA to work with other organizations to
complete and publish the 4 guidelines noted above and
make them available to the widest possible constituency.
Recognizing that the Expert Panels/Work Groups did not
consider evidence beyond 2011 (except as speciﬁed in the
methodology), the ACC, AHA, and collaborating societies
plan to begin updating these guidelines starting in 2014.
The joint ACC/AHA Task Force on Practice Guide-
lines (Task Force) appointed a subcommittee to shepherd
this transition, communicate the rationale and expectations
to the writing panels and partnering organizations, and
expeditiously publish the documents. The ACC/AHA and
partner organizations recruited a limited number of expert
reviewers for ﬁduciary examination of content, recognizing
that each document had undergone extensive peer review
by representatives of the NHLBI Advisory Council, key
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2962federal agencies, and scientiﬁc experts. Each writing panel
responded to comments from these reviewers. Clariﬁca-
tions were incorporated where appropriate, but there were
no substantive changes because the bulk of the content was
undisputed.
Although the Task Force led the ﬁnal development of
these prevention guidelines, they differ from other ACC/
AHA guidelines. First, as opposed to an extensive com-
pendium of clinical information, these documents are
signiﬁcantly more limited in scope and focus on selected
CQs on each topic, based on the highest-quality evidence
available. Recommendations were derived from random-
ized trials, meta-analyses, and observational studies evalu-
ated for quality and were not formulated when sufﬁcient
evidence was not available. Second, the text accompanying
each recommendation is succinct, summarizing the evi-
dence for each question. The Full Panel/Work Group
Reports include more detailed information about the evi-
dence statements (ESs) that serve as the basis for recom-
mendations. Third, the format of the recommendations
differs from other ACC/AHA guidelines. Each recom-
mendation has been mapped from the NHLBI grading
format to the ACC/AHA Classiﬁcation of Recommen-
dation/Level of Evidence (COR/LOE) construct (Table 1)
and is expressed in both formats. Because of the inherent
differences in grading systems and the clinical questions
driving the recommendations, alignment between the
NHLBI and ACC/AHA formats is in some cases
imperfect. Explanations of these variations are noted in the
recommendation tables, where applicable.
In consultation with NHLBI, the policies adopted by
the writing panels to manage relationships of authors with
industry and other entities (RWI) are outlined in the
methods section of each panel report. These policies were
in effect when this effort began in 2008 and throughout
the writing process and voting on recommendations, until
the process was transferred to ACC/AHA in 2013. In the
interest of transparency, the ACC/AHA requested that
panel authors resubmit RWI disclosures as of July 2013.
Relationships relevant to this guideline are disclosed in
Appendix 1. None of the ACC/AHA expert reviewers had
relevant RWI (Appendix 2). See Appendix 3 for a list of
abbreviations used in the guideline.
Systematic evidence reports and accompanying summary
tables were developed by the expert panels and NHLBI.
The guideline was reviewed by the ACC/AHA Task Force
and approved by the ACC Board of Trustees and the
AHA Science Advisory and Coordinating Committee. In
addition, ACC/AHA sought endorsement from other
stakeholders, including professional organizations. It is the
hope of the writing panels, stakeholders, professional or-
ganizations, NHLBI, and Task Force that the guidelines
will garner the widest possible readership for the beneﬁt of
patients, providers, and the public health.
These guidelines are meant to deﬁne practices that
meet the needs of patients in most circumstances andare not a replacement for clinical judgment. The ulti-
mate decision about care of a particular patient must be
made by the healthcare provider and patient in light of
the circumstances presented by that patient. As a result,
situations might arise in which deviations from these
guidelines may be appropriate. These considerations
notwithstanding, in caring for most patients, clinicians
can employ the recommendations conﬁdently to reduce
the risks of atherosclerotic CVD events.
See Tables 2 and 3 for an explanation of the NHLBI
recommendation grading methodology.
1.1. Scope of Guideline
See Table 4 for the Lifestyle Expert Work Group’s CQs.
A healthy lifestyle is important in the prevention of
CVD, the leading cause of morbidity and mortality
worldwide. The intent of the Lifestyle Work Group
(Work Group) was to evaluate evidence that particular
dietary patterns, nutrient intake, and levels and types of
physical activity can play a major role in CVD prevention
and treatment through effects on modiﬁable CVD risk
factors (i.e., blood pressure [BP] and lipids). These ESs
and recommendations may be used as appropriate in the
management of hypercholesterolemia and hypertension.
The target audience of the report is primary care providers.
This guideline is based on the Full Work Group Report,
which is provided as an online-only data supplement to the
guideline. The Full Work Group Report supplement
contains background and additional material related to
content, methodology, evidence synthesis, rationale, and
references and is supported by the NHLBI Systematic
Evidence Review, which can be found at http://www.nhlbi.
nih.gov/guidelines/cvd_adult/lifestyle/.
Diet and physical activity interventions of interest to the
Work Group that were not included in this report because
of time and resource limitations were the following: cal-
cium, magnesium, alcohol, cardiorespiratory ﬁtness, single
behavioral intervention or multicomponent lifestyle in-
terventions, the addition of lifestyle intervention to phar-
macotherapy, and smoking. Outcomes of interest not
covered in this evidence review were the following risk
factors: diabetes mellitus (diabetes)- and obesity-related
measurements, incident diabetes metabolic syndrome,
high-sensitivity C-reactive protein, and other inﬂamma-
tory markers. The Work Group was interested in review-
ing the evidence for CVD outcomes in all of the CQs;
however, the evidence for mortality and CVD outcomes
was reviewed only in CQ2.
1.2. Methodology and Evidence Review
1.2.1. Scope of the Evidence Review
To formulate the nutrition recommendations, the Work
Group used randomized controlled trials (RCTs), obser-
vational studies, meta-analyses, and systematic reviews of
studies carried out in adults (18 years of age) with or
Table 1. Applying Classiﬁcation of Recommendation and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials.
Even when randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
*Data available from clinical trials or registries about the usefulness/efﬁcacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart
failure, and prior aspirin use.
yFor comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments
or strategies being evaluated.
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or without risk factors for coronary heart disease/CVD,
who were of normal weight, overweight, or obese. The
evidence review date range was 1998 to 2009. To capture
historical data or more recent evidence, date ranges were
changed for subquestions in some instances. The evidence
date ranges are described clearly in each CQ section. The
Work Group assessed the impact of both dietary patterns
and macronutrient composition on plasma low-density li-
poprotein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), and triglycerides and on systolic BP
and diastolic BP over a minimum RCT intervention
period of 1 month in studies performed in any geographic
location and research setting.Overall, the Work Group emphasized dietary patterns
rather than individual dietary components. Patterns were
characterized by habitual or prescribed combinations of
daily food intake. Dietary patterns offer the opportunity to
characterize the overall composition and quality of the
eating behaviors of a population (e.g., Mediterranean-style
dietary [MED] pattern). Eating patterns consist of various
combinations of foods that may differ in macronutrient,
vitamin, and mineral compositions. The macronutrients
saturated, trans, monounsaturated, and polyunsaturated
fatty acids are particularly relevant for their effects on plasma
lipids and lipoproteins. Dietary sodium and potassium are
particularly relevant for their effects on BP. Epidemiological
research has examined the dietary patterns of populations
Table 2. NHLBI Grading of the Strength of
Recommendations
Grade Strength of Recommendation*
A Strong recommendation
There is high certainty based on evidence that the net beneﬁty
is substantial.
B Moderate recommendation
There is moderate certainty based on evidence that the net beneﬁt is
moderate to substantial, or there is high certainty that the net
beneﬁt is moderate.
C Weak recommendation
There is at least moderate certainty based on evidence that there is a
small net beneﬁt.
D Recommendation against
There is at least moderate certainty based on evidence that there is
no net beneﬁt or that risks/harms outweigh beneﬁts.
E Expert opinion (“There is insufﬁcient evidence or evidence is
unclear or conﬂicting, but this is what the Work Group
recommends.”)
Net beneﬁt is unclear. Balance of beneﬁts and harms cannot be
determined because of no evidence, insufﬁcient evidence,
unclear evidence, or conﬂicting evidence, but the Work Group
thought it was important to provide clinical guidance and
make a recommendation. Further research is recommended
in this area.
N No recommendation for or against (“There is insufﬁcient evidence or
evidence is unclear or conﬂicting.”)
Net beneﬁt is unclear. Balance of beneﬁts and harms cannot be
determined because of no evidence, insufﬁcient evidence, unclear
evidence, or conﬂicting evidence, and the Work Group thought
no recommendation should be made. Further research is
recommended in this area.
*In most cases, the strength of the recommendation should be closely aligned with the quality
of the evidence; however, under some circumstances, there may be valid reasons for making
recommendations that are not closely aligned with the quality of the evidence (e.g., strong
recommendation when the evidence quality is moderate, such as smoking cessation to reduce
cardiovascular disease risk or ordering an ECG as part of the initial diagnostic work-up for a
patient presenting with possible MI). Those situations should be limited and the rationale
explained clearly by the Work Group.
yNet beneﬁt is deﬁned as beneﬁts minus risks/harms of the service/intervention.
ECG indicates electrocardiogram; MI, myocardial infarction; and NHLBI, National Heart, Lung,
and Blood Institute.
Table 3. NHLBI Quality Rating of the Strength of Evidence
Type of Evidence Quality Rating*
Well-designed, well-executedy RCT that adequately
represent populations to which the results are applied
and directly assess effects on health outcomes.
Meta-analyses of such studies.
Highly certain about the estimate of effect. Further
research is unlikely to change our conﬁdence in the
estimate of effect.
High
RCT with minor limitationsz affecting conﬁdence in,
or applicability of, the results.
Well-designed, well-executed nonrandomized controlled
studiesx and well-designed, well-executed observational
studiesk.
Meta-analyses of such studies.
Moderately certain about the estimate of effect. Further
research may have an impact on our conﬁdence in the
estimate of effect and may change the estimate.
Moderate
RCT with major limitations.
Nonrandomized controlled studies and observational
studies with major limitations affecting conﬁdence in,
or applicability of, the results.
Uncontrolled clinical observations without an appropriate
comparison group (e.g., case series, case reports).
Physiological studies in humans.
Meta-analyses of such studies.
Low certainty about the estimate of effect. Further
research is likely to have an impact on our conﬁdence
in the estimate of effect and is likely to change the
estimate.
Low
*In some cases, other evidence, such as large all-or-none case series (e.g., jumping from air-
planes or tall structures), can represent high- or moderate-quality evidence. In such cases, the
rationale for the evidence rating exception should be explained by the Work Group and clearly
justiﬁed.
y“Well-designed, well-executed” refers to studies that directly address the question; use
adequate randomization, blinding, and allocation concealment; are adequately powered; use
intention-to-treat analyses; and have high follow-up rates.
zLimitations include concerns with the design and execution of a study that result in decreased
conﬁdence in the true estimate of the effect. Examples of such limitations include but are not
limited to: inadequate randomization, lack of blinding of study participants or outcome asses-
sors, inadequate power, outcomes of interest that are not prespeciﬁed for the primary out-
comes, low follow-up rates, and ﬁndings based on subgroup analyses. Whether the limitations
are considered minor or major is based on the number and severity of ﬂaws in design or
execution. Rules for determining whether the limitations are considered minor or major and how
they will affect rating of the individual studies will be developed collaboratively with the meth-
odology team.
xNonrandomized controlled studies refer to intervention studies where assignment to inter-
vention and comparison groups is not random (e.g., quasi-experimental study design).
kObservational studies include prospective and retrospective cohort, case-control, and cross-
sectional studies.
NHLBI indicates National Heart, Lung, and Blood Institute; and RCT, randomized controlled
trials.
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CVD risk factors and outcomes. Intervention studies have
tested a priori hypotheses involving prescribed dietary pat-
terns speciﬁcally formulated on the basis of these data (e.g.,
Dietary Approaches to Stop Hypertension [DASH] or
MED patterns). Population-based prospective cohort
studies and RCTs suggest that there are healthier overall
dietary patterns (foods and/or their constituent macronu-
trient, vitamin, and mineral combinations) that are associ-
ated with lower risk of chronic diseases, including CVD and
risk factors such as type 2 diabetes and hypertension. We
reviewed data exclusively on dietary intake rather than
nutritional supplements provided in pharmaceutical prep-
arations (e.g., potassium pills), because nutritional sup-
plements may not have similar effects and are not
considered “lifestyle” interventions.
The Work Group focused on CVD risk factors to
provide a free-standing Lifestyle document and to inform
the Blood Cholesterol guideline (4) and the hypertension
panel. It also recognized that RCTs examining the effectson hard outcomes (myocardial infarction, stroke, heart
failure, and CVD-related death) are difﬁcult if not
impossible to conduct for several reasons (e.g., long-term
adherence to dietary changes). However, the Work
Group also supplemented this evidence on risk factors with
observational data on hard outcomes for sodium. The
Work Group prioritized topics for the evidence review and
was unable to review the evidence on hard outcomes for
dietary patterns or physical activity.
For physical activity, substantial epidemiological evi-
dence links higher levels of aerobic physical activity to
lower rates of CVD and other chronic diseases, such as
type 2 diabetes. Evidence indicates a dose-dependent in-
verse relationship between levels of physical activity and
rates of CVD. The proposed mechanisms mediating the
Table 4. Critical Questions
Critical Questions:
CQ1. Among adults*, what is the effect of dietary patterns and/or
macronutrient composition on CVD risk factors, when compared
with no treatment or with other types of interventions?
CQ2. Among adults, what is the effect of dietary intake of sodium and
potassium on CVD risk factors and outcomes, when compared
with no treatment or with other types of interventions?
CQ3. Among adults, what is the effect of physical activity on BP and lipids
when compared with no treatment or with other types of
interventions?
*Those 18 years of age and <80 years of age.
BP indicates blood pressure; CQ, critical question; and CVD, cardiovascular disease.
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2965relationship between physical activity and decreased CVD
rates include beneﬁcial effects on lipids, lipoproteins, BP,
and type 2 diabetes. The search for evidence related to
physical activity and CVD included only systematic
reviews and meta-analyses of RCTs or individual controlled
clinical trials in adults (18 years of age) that were pub-
lished from 2001 to 2011. For this CQ, the intervention was
deﬁned as physical activity interventions of any type.
Weight loss and maintenance are crucial for prevention
and control of CVD risk factors. The Obesity Expert Panel
simultaneously performed a systematic review of the evidence
for weight management and CVD risk factors and outcomes
(5). The primary intent of the Work Group’s systematic
review was to focus on the effects of diet and physical activity
on CVD risk factors independent of effects on weight.
Therefore, studies in which the primary outcome was weight
loss or in which treatment was associated with >3% change
in weight were excluded from the present review. However,
the Work Group expects that recommendations from both
evidence reviews will apply to many patients.
Because of limited resources and time, the Work Group
could not review every study pertaining to lifestyle and
CVD risk factors and outcomes. Priority was given to
strong study design and a contemporaneous timeframe
(1998 to 2009). However, there were instances in which
the evidence review was extended beyond that timeframe.
Landmark evidence on the effect of fatty acids on lipids
was included back to 1990. The sodium evidence review
included evidence through April 2012, and the physical
activity meta-analysis review was extended to May 2011.
Given the expertise of Work Group members and their
familiarity with the literature in this ﬁeld, the Work Group
is conﬁdent that a broader review would not substantially
change our conclusions or recommendations.
The results of the Work Group systematic review are the
10 lifestyle recommendations (8 dietary and 2 physical
activity recommendations) (Table 5). Because the Work
Group was convened to inform the development of clinical
guidelines, and because most data meeting our criteria for
review were derived from studies of high-risk populations,
these recommendations are directed at patients with CVD
risk factors (i.e., abnormal lipids and/or prehypertension
and hypertension). The majority of adults in the UnitedStates currently have 1 of these risk factors (33.5%
with elevated LDL-C; 27.3%, hypertension; 31%, pre-
hypertension; and 11.3%, diabetes), with risk factors
increasing with age (6). The Work Group encourages
heart-healthy nutrition and physical activity behaviors for
all adults (Section 5.6) (Table 17).
For both BP and lipids, most studies of diet and/or
physical activity exclude people taking antihypertensive or
lipid-lowering medications. Although there is no direct
evidence, it is reasonable to expect that the beneﬁcial ef-
fects of these lifestyle recommendations apply to those
taking such medications and that following these rec-
ommendations can potentially lead to better BP and lipid
control in those taking medications and/or reduced
medication needs. The recommendations apply to
adults <80 years of age with and without CVD.
1.2.2. CQ-Based Approach
The Work Group developed an initial set of questions
based on their expertise and a brief literature review to
identify topics of the greatest relevance and impact for the
target audience of the guideline: primary care providers
Because of time and resource limitations, the Work Group
prioritized the 3 CQs in Table 4.
The body of this report is organized byCQ. For eachCQ:
 The rationale for its selection is provided, and
methods are described.
 The ESs are presented, which include a rating for
quality, a rationale that supports each item of evi-
dence, and a statement. A detailed description of
methods is provided in the NHLBI Lifestyle Sys-
tematic Evidence Review Report (http://www.nhlbi.
nih.gov/guidelines/cvd_adult/lifestyle/). The Full
Work Group Report supplement presents docu-
mentation for search strategies and results from
the search of the published literature.
 Recommendations include recommendation strength,
accompanied by a summary of how the recommen-
dation derives from the evidence and a discussion of
issues considered by the Work Group in formulating
the recommendation. The ACC/AHA COR/LOE
ratings have also been added.
The ESs and recommendations are presented by CQ
and grouped by topic:
 CQ1 presents evidence on dietary patterns and
macronutrients and their effect on BP and lipids.
The dietary recommendations for LDL-C lowering
are described at the end of CQ1.
 CQ2 presents the evidence on the effect of dietary
sodium and potassium intake on BP and CVD
outcomes. The dietary recommendations for BP
lowering are located at the end of CQ2.
 Finally, CQ3 presents evidence on the effect of
physical activity on lipids and BP and physical
Table 5. Summary of Recommendations for Lifestyle Management
Recommendations NHLBI Grade
NHLBI Evidence
Statements ACC/AHA COR ACC/AHA LOE
DIET
LDL-C: Advise adults who would beneﬁt from LDL-C lowering* to:
1. Consume a dietary pattern that emphasizes intake of
vegetables, fruits, and whole grains; includes low-fat
dairy products, poultry, ﬁsh, legumes, nontropical
vegetable oils, and nuts; and limits intake of sweets,
sugar-sweetened beverages, and red meats.
a. Adapt this dietary pattern to appropriate calorie
requirements, personal and cultural food preferences,
and nutrition therapy for other medical conditions
(including diabetes).
b. Achieve this pattern by following plans such as the DASH
dietary pattern, the USDA Food Pattern, or the AHA Diet.
A (Strong) CQ1: ES4 (high), ES6 (low),
ES8 (moderate),
ES9 (moderate)
I A
2. Aim for a dietary pattern that achieves 5%–6% of calories
from saturated fat.
A (Strong) CQ1: ES11 (high) I A
3. Reduce percent of calories from saturated fat. A (Strong) CQ1: ES11 (high),
ES12 (moderate),
ES13 (moderate)
I A
4. Reduce percent of calories from trans fat. A (Strong) CQ1: ES14 (moderate),
ES15 (moderate)
I A
BP: Advise adults who would beneﬁt from BP lowering to:
1. Consume a dietary pattern that emphasizes intake of
vegetables, fruits, and whole grains; includes low-fat
dairy products, poultry, ﬁsh, legumes, nontropical
vegetable oils, and nuts; and limits intake of sweets,
sugar-sweetened beverages, and red meats.
a. Adapt this dietary pattern to appropriate calorie
requirements, personal and cultural food preferences,
and nutrition therapy for other medical conditions
(including diabetes).
b. Achieve this pattern by following plans such as the DASH
dietary pattern, the USDA Food Pattern, or the AHA Diet.
A (Strong) CQ1: ES1 (low) ES3 (high),
ES5 (high), ES6 (low),
ES7 (low),
ES8 (moderate)
I A
2. Lower sodium intake. A (Strong) CQ2: ES1 (high),
ES2 (moderate),
ES3 (high), ES4 (high),
ES5 (high), ES8 (low),
ES9 (low)
I A
3. a. Consume no more than 2,400 mg of sodium/d;
b. Further reduction of sodium intake to 1,500 mg/d
can result in even greater reduction in BP; and
c. Even without achieving these goals, reducing
sodium intake by at least 1,000 mg/d lowers BP.
B (Moderate) CQ2: ES2 (moderate),
ES3 (high)
IIa B
4. Combine the DASH dietary pattern with lower sodium intake. A (Strong) CQ1: ES3 (high), ES5 (high),
ES8 (moderate)
CQ2: ES1 (high),
ES2 (moderate),
ES3 (high), ES4 (high),
ES5 (high), ES6 (moderate)
I A
PHYSICAL ACTIVITY
Lipids
1. In general, advise adults to engage in aerobic physical
activity to reduce LDL-C and non–HDL-C: 3–4 sessions per wk,
lasting on average 40 min per session, and involving
moderate- to vigorous-intensity physical activity.
B (Moderate) CQ3: ES1 (moderate),
ES2 (moderate),
ES5 (low)
IIa A
BP
1. In general, advise adults to engage in aerobic physical
activity to lower BP: 3–4 sessions per wk, lasting on average
40 min per session, and involving moderate- to
vigorous-intensity physical activity.
B (Moderate) CQ3: ES1 (high) IIa A
*Refer to 2013 Blood Cholesterol Guideline for guidance on who would beneﬁt from LDL-C lowering (4).
ACC indicates American College of Cardiology; AHA, American Heart Association; BP, blood pressure; COR, Class of Recommendation; CQ, critical question; DASH, Dietary Approaches to Stop
Hypertension; ES, evidence statement; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LOE, Level of Evidence; NHLBI, National Heart, Lung, and Blood Institute;
and USDA, U.S. Department of Agriculture.
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2967activity recommendations for BP and lipid lowering.
The physical activity recommendations for BP and
lipid lowering are located at the end of CQ3.
It should be recognized that formulating recommen-
dations derived from evidence reviews in response to
CQs has some advantages as well as limitations. Because
of its desire to adhere to the highest quality of evidence,
the Work Group was restricted to using evidence that
met inclusion/exclusion and quality criteria established
by the Work Group in partnership with the methodol-
ogists. When the phrase “there is insufﬁcient evidence” is
used, the reader must distinguish between “insufﬁcient”
evidence where no studies meeting inclusion/exclusion
and quality criteria were found to answer a CQ and
“insufﬁcient” evidence where RCTs or observational
studies were conducted but the available data do not
provide sufﬁcient information to formulate a recommen-
dation. This perspective is important because clinicians
could see fewer recommendations derived from expert
opinion. Given this perspective, the clinical and research
community can identify research questions that need to be
answered in the future to reﬁne recommendations when
updates to the guideline are written (Section 6).
1.3. Organization of Work Group
The Work Group was composed of 12 members and 4 ex-
ofﬁcio members, including physicians and experts in BP,
blood cholesterol, obesity, and lifestyle management. The
authors came from the primary care, nursing, pharma-
cology, nutrition, exercise, behavioral science, and epide-
miology disciplines and also included senior scientiﬁc staff
from NHLBI and the National Institutes of Health.
1.4. Document Reviews and Approval
A formal peer review process initially was completed under
the auspices of the NHLBI and included 6 expert reviewers
and representatives of federal agencies. This document was
also reviewed by 4 expert reviewers nominated by the ACC
and the AHA when the management of the guideline
transitioned to the ACC/AHA. The ACC and AHA
reviewers’ RWI information is published in this document
(Appendix 2).
This document was approved for publication by the gov-
erning bodies of the ACC and AHA and endorsed by the
American Association of Cardiovascular and Pulmonary
Rehabilitation, American Pharmacists Association, Amer-
ican Society for Nutrition, American Society for Preventive
Cardiology, American Society of Hypertension, Association
of Black Cardiologists, National Lipid Association, Preven-
tive Cardiovascular Nurses Association, and WomenHeart:
The National Coalition for Women With Heart Disease.
2. Lifestyle Management Recommendations
See Table 5 for the Summary of Lifestyle Recommendations.3. CQ1dDietary Patterns and
Macronutrients: BP and Lipids
See Table 6 for the CQ for BP and lipids with dietary
patterns and macronutrients.
3.1. Introduction/Rationale
The importance of nutrition in modifying the risk of CVD
has been repeatedly emphasized (7–11). Historically, the
role of dietary components has been the predominant focus;
however, foods are typically consumed in combinations
rather than individually. Over the past few years, increasing
attention has been given to dietary patterns and their rela-
tionship to health outcomes such as CVD (12–20).
In intervention studies, speciﬁc dietary patterns of
deﬁned macronutrient composition are identiﬁed on the
basis of expert evidence and a priori hypothesis (e.g., the
DASH or MED patterns) and then are evaluated in RCTs.
In observational studies, associations between intake and
risk factors are assessed. Because of resource limitations,
CVD morbidity and mortality outcomes were not included
in the evidence review for this question. The charge of the
Work Group was to inform the treatment of lipids and BP;
therefore, those risk factors were the outcomes of focus.
3.2. Selection of Inclusion/Exclusion Criteria
Work Group members developed eligibility criteria based
on a Population, Intervention, Comparator, Outcomes,
Timing, and Setting (PICOTS) approach for screening
potential studies for inclusion in this evidence review. The
details of the PICOTS approach for CQ1 and Literature
Search Yield, including summary tables, are available in the
Full Work Group Report supplement.
3.3. Literature Search Yield
3.3.1. Dietary Pattern/Macronutrient
Composition Evidence
In all, 17 studies (28 articles) satisﬁed the ﬁnal inclusion
criteria and were rated to be of good or fair quality (21–48).
The Dietary Pattern Summary Tables (Tables B–1
through B–8) are available in the Full Work Group Report
supplement. The tables present summary data on the
included studies organized by dietary pattern/macronu-
trient composition or subpopulations of interest, deﬁned by
age, sex, race, or comorbid condition. Some studies appear
in more than 1 summary table because they address more
than 1 corresponding macronutrient composition or di-
etary pattern comparison.
3.4. CQ1 Evidence Statements
3.4.1. Dietary Patterns
3.4.1.1. MED PATTERN
MED pattern description (Table 7): There was no uni-
form deﬁnition of the MED diet in the RCTs and cohort
Table 6. CQ for Dietary Patterns and Macronutrients:
BP and Lipids
CQ1:
Among adults, what is the effect of dietary patterns and/or macronutrient
composition on CVD risk factors, when compared with no treatment or with
other types of interventions?
BP indicates blood pressure; CQ, critical question; and CVD, cardiovascular disease.
Table 8. ESs for BP and Lipids With the DASH Pattern
BP
ES3.
 When all food was supplied to adults with BP 120–159/80–95 mm Hg
and both body weight and sodium intake were kept stable, the DASH
dietary pattern, compared with a typical American diet of the 1990s,
lowered BP by 5–6/3 mm Hg.
Strength of Evidence: High
Lipids
ES4.
 When food was supplied to adults with a total cholesterol level<260mg/dL
and LDL-C level <160 mg/dL and body weight was kept stable, the
DASH dietary pattern, compared with a typical American diet of the
1990s, lowered LDL-C by 11 mg/dL, lowered HDL-C by 4 mg/dL, and
had no effect on triglycerides.
Strength of Evidence: High
DASH DIETARY PATTERN SUBPOPULATIONS
Subpopulations and BP
ES5.
 When all food was supplied to adults with BP 120–159/80–95 mm Hg
and body weight was kept stable, the DASH dietary pattern, compared
with the typical American diet of the 1990s, lowered BP in women and
men, African-American and non–African-American adults, older and
younger adults, and hypertensive and nonhypertensive adults.
Strength of Evidence: High
Subpopulations and Lipids
ES6.
 When all food was supplied to adults with a total cholesterol
level <260 mg/dL and LDL-C level <160 mg/dL and body weight was
kept stable, the DASH dietary pattern, compared with a typical American
diet of the 1990s, lowered LDL-C similarly in subgroups: African-American
and non–African-American adults and hypertensive and nonhypertensive
adults.
Strength of Evidence: Low
ES7.
 When all food was supplied to adults with a total cholesterol level <260
mg/dL and LDL-C level <160 mg/dL and body weight was kept stable,
the DASH dietary pattern, compared with a typical American diet of the
1990s, lowered HDL-C similarly in subgroups: African-American and non–
African-American adults, hypertensive and nonhypertensive adults, and
men and women.
Strength of Evidence: Low
BP indicates blood pressure; DASH, Dietary Approaches to Stop Hypertension; ES, evidence
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these studies were that they were higher in fruits (partic-
ularly fresh), vegetables (emphasizing root and green va-
rieties), whole grains (cereals, breads, rice, or pasta), and
fatty ﬁsh (rich in omega-3 fatty acids); were lower in red
meat (emphasizing lean meats); substituted lower-fat or
fat-free dairy products for higher-fat dairy foods; and used
oils (olive or canola), nuts (walnuts, almonds, or hazelnuts),
or margarines blended with rapeseed or ﬂaxseed oils in lieu
of butter and other fats. The MED patterns examined
tended to be moderate in total fat (32% to 35% of total
calories), relatively low in saturated fat (9% to 10% of total
calories), high in ﬁber (27 to 37 g/d), and high in poly-
unsaturated fatty acids (particularly omega-3s).
3.4.1.2. DASH DIETARY PATTERN
DASH dietary pattern description (Table 8): The
DASH dietary pattern is high in vegetables, fruits, low-fat
dairy products, whole grains, poultry, ﬁsh, and nuts and is
low in sweets, sugar-sweetened beverages, and red meats.
The DASH dietary pattern is low in saturated fat, total fat,
and cholesterol. It is rich in potassium, magnesium, and
calcium, as well as protein and ﬁber.
3.4.1.3. DASH VARIATIONS
DASH variations description (Table 9): In OmniHeart
(Optimal Macronutrient Intake Trial for Heart Health),
2 variations of the DASH dietary pattern were compared
with DASH: one that replaced 10% of total daily energy
from carbohydrate with protein, and another that replacedTable 7. ESs for BP and Lipids With the MED Pattern
BP
ES1.
 Counseling to eat a MED pattern, as compared with minimal advice to
consume a low-fat dietary pattern, in free-living middle-aged or older
adults (with type 2 diabetes or at least 3 CVD risk factors) reduced BP
by 6–7/2–3 mm Hg. In an observational study of healthy younger
adults, adherence to a MED pattern was associated with lower BP
(2–3/1–2 mm Hg).
Strength of Evidence: Low
Lipids
ES2.
 Counseling to eat a MED pattern, compared with minimal or no dietary
advice, in free-living middle-aged or older adults (with or without CVD or at
high risk for CVD) resulted in no consistent effect on plasma LDL-C, HDL-C,
and triglycerides, in part because of substantial differences and
limitations in the studies.
Strength of Evidence: Low
BP indicates blood pressure; CVD, cardiovascular disease; ES, evidence statement; HDL-C,
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and MED,
Mediterranean-style dietary pattern.
statement; HDL-C, high-density lipoprotein cholesterol.the same amount of carbohydrate with unsaturated fat.
These patterns were studied in an adequately powered
crossover trial of 164 adults in which the participants were
given all of their daily food.
3.4.2. Dietary Fat and Cholesterol
See Table 10 for ESs for saturated fat, trans fat, and dietary
cholesterol.
3.5. Diet Recommendations for LDL-C Lowering*
The following diet recommendations for LDL-C lowering
are based on the ESs from CQ1 on dietary patterns and
fatty acids. Diet recommendations for BP lowering are
based on CQ1 and CQ2 and are located after the CQ2*Refer to the 2013 Blood Cholesterol Guideline (4) for guidance on who would
beneﬁt from LDL-C lowering.
Table 9. ESs for DASH Variations/Glycemic Index/Load
Dietary Approaches
BP
ES8.
 In adults with BP of 120–159/80–95 mm Hg, modifying the DASH dietary
pattern by replacing 10% of calories from carbohydrates with the same
amount of either protein or unsaturated fat (8% monounsaturated and 2%
polyunsaturated) lowered systolic BP by 1 mm Hg compared with the
DASH dietary pattern. Among adults with BP 140–159/90–95 mm Hg,
these replacements lowered systolic BP by 3 mm Hg relative to DASH.
Strength of Evidence: Moderate
Lipids
ES9.
 In adults with average baseline LDL-C level of 130 mg/dL, HDL-C level of
50 mg/dL, and triglyceride level of 100 mg/dL, modifying the DASH
dietary pattern by replacing 10% of calories from carbohydrates with 10%
of calories from protein lowered LDL-C by 3 mg/dL, HDL-C by 1 mg/dL,
and triglycerides by 16 mg/dL compared with the DASH dietary pattern.
Replacing 10% of calories from carbohydrates with 10% of calories from
unsaturated fat (8% monounsaturated and 2% polyunsaturated) lowered
LDL-C similarly, increased HDL-C by 1 mg/dL, and lowered triglycerides by
10 mg/dL as compared with the DASH dietary pattern.
Strength of Evidence: Moderate
ES10.
 There is insufﬁcient evidence to determine whether low-glycemic diets
versus high-glycemic diets affect lipids or BP for adults without
diabetes. The evidence for this relationship in adults with diabetes was
not reviewed.
Strength of Evidence: Insufﬁcient
BP indicates blood pressure; DASH, Dietary Approaches to Stop Hypertension; ES, evidence
statement; HDL-C, high-density lipoprotein cholesterol; and LDL-C, low-density lipoprotein
cholesterol.
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mendations are located in CQ3.
1. Advise adults who would beneﬁt from LDL-C
lowering to:
 Consume a dietary pattern that emphasizes
intake of vegetables, fruits, and whole grains;
includes low-fat dairy products, poultry, ﬁsh,
legumes, nontropical vegetable oils, and nuts;
and limits intake of sweets, sugar-sweetened
beverages, and red meats.
B Adapt this dietary pattern to appropriate cal-
orie requirements, personal and cultural food
preferences, and nutrition therapy for other
medical conditions (including diabetes).
B Achieve this pattern by following plans such
as the DASH dietary pattern, the U.S.
Department of Agriculture (USDA) Food
Pattern, or the AHA Diet.NHLBI Grade: A (Strong); ACC/AHA COR: I, LOE: A
Rationale: This recommendation is based largely on
studies of the DASH dietary pattern (DASH and DASH-
Sodium), which provided the highest-quality evidence for a
dietary pattern causing improvements in BP and lipid
proﬁles (Tables 8 and 9). The LDL-C–lowering effect has
been demonstrated in men and women, African Americans
and non–African Americans, and in adults of all ages
(Table 8, ES6). The evidence suggests that the effects ofthe recommended dietary pattern persist as long as the
pattern is consumed.
The caloric (energy) intake should be appropriate for the
individual (e.g., restricted for those attempting weight
loss). Patients should also be encouraged to adapt the
recommended dietary pattern to their personal and cultural
preferences. Materials are available to assist patients in
achieving the recommended dietary pattern at different
calorie levels (Table 9). The 2010 U.S. Department of
Health and Human Services Dietary Guidelines for
Americans recommend the USDA Food Pattern and the
DASH dietary pattern (49). Overall, the recommended
dietary pattern is consistent with the AHA Diet (50) and
the USDA Food Pattern (49). The USDA Food Pattern
offers lacto-ovo vegetarian and vegan adaptations. There-
fore, this recommendation is consistent with other national
guidelines. Clinicians should be familiar with the recom-
mendations, advise their patients to adopt them, and
provide easy access to information (Table 11). Dietary
planning and nutritional counseling are often facilitated by
referral to a nutrition professional.
2. Advise adults who would beneﬁt from LDL-C
lowering to:
 Aim for a dietary pattern that achieves 5% to
6% of calories from saturated fat.NHLBI Grade: A (strong); ACC/AHA COR: I, LOE: A
Rationale: As described in Table 10, ES11 there is strong
evidence that reductions in LDL-C were achieved when
dietary patterns were followed in which saturated fat intake
was reduced from 14% to 15% of calories to 5% to 6%. As
previously noted, these studies did not isolate the effect of
saturated fat on LDL-C lowering. Intake of saturated fat
has decreased in the United States over the past few de-
cades and is currently estimated at 11% of energy in the
U.S. population 2 years of age (51). However, this level
of saturated fat intake is higher than that tested in the
DASH and DELTA (Dietary Effects on Lipoproteins and
Thrombogenic Activity) trials (5% to 6%) and is not
consistent with consuming a diet rich in vegetables, fruits,
low-fat dairy products, whole grains, poultry, ﬁsh, legumes
and nuts, and vegetable oils and limited in sweets, sugar-
sweetened beverages, and red meat. Given the current
average intake of saturated fat at 11% of calories, it would
be beneﬁcial for those who would beneﬁt from LDL-C
lowering to decrease saturated fat intake to 5% to 6% of
calories.
3. Advise adults who would beneﬁt from LDL-C
lowering to:
 Reduce percentage of calories from saturated
fat.NHLBI Grade: A (strong); ACC/AHA COR: I, LOE: A
Rationale: Reducing saturated fat intake lowers both
LDL-C and HDL-C. Because the absolute effect tends to
Table 10. ESs for Dietary Fat and Cholesterol
Saturated Fat
ES11.
 When food was supplied to adults in a dietary pattern that achieved a macronutrient composition of 5%–6% saturated fat, 26%–27% total fat, 15%–18% protein,
and 55%–59% carbohydrate compared with the control diet (14%–15% saturated fat, 34%–38% total fat, 13%–15% protein, and 48%–51% carbohydrate), LDL-C
was lowered 11–13 mg/dL in 2 studies and 11% in another study.
Strength of Evidence: High
ES12.
 In controlled feeding trials among adults, for every 1% of energy from SFA that is replaced by 1% of energy from carbohydrate, MUFA, or PUFA:
 LDL-C is lowered by an estimated 1.2, 1.3, and 1.8 mg/dL, respectively.
 HDL-C is lowered by an estimated 0.4, 1.2, and 0.2 mg/dL, respectively.
 For every 1% of energy from SFA that is replaced by 1% of energy from:
 Carbohydrate and MUFA:
 Triglycerides are raised by an estimated 1.9 and 0.2 mg/dL, respectively.
 PUFA:
 Triglycerides are lowered by an estimated 0.4 mg/dL.
Strength of Evidence: Moderate
ES13.
 In controlled feeding trials among adults, for every 1% of energy from carbohydrate that is replaced by 1% of energy from:
 MUFA:
 LDL-C is lowered by 0.3 mg/dL, HDL-C is raised by 0.3 mg/dL, and triglycerides are lowered by 1.7 mg/dL.
 PUFA:
 LDL-C is lowered by 0.7 mg/dL, HDL-C is raised by 0.2 mg/dL, and triglycerides are lowered by 2.3 mg/dL.
Strength of Evidence: Moderate
Trans Fat
ES14.
 In controlled feeding trials among adults, for every 1% of energy from trans monounsaturated fatty acids replaced with 1% of energy from:
 MUFA or PUFA
 LDL-C is lowered by 1.5 mg/dL and 2.0 mg/dL, respectively.
 SFA, MUFA, or PUFA:
 HDL-C is increased by an estimated 0.5, 0.4, and 0.5 mg/dL, respectively.
 MUFA or PUFA:
 Triglycerides are decreased by an estimated 1.2 and 1.3 mg/dL.
Strength of Evidence: Moderate
ES15.
 In controlled feeding trials among adults, the replacement of 1% of energy as trans monounsaturated fatty acids with carbohydrate decreased LDL-C levels by
1.5 mg/dL and had no effect on HDL-C cholesterol and triglyceride levels.
Strength of Evidence: Moderate
Dietary Cholesterol
ES16.
 There is insufﬁcient evidence to determine whether lowering dietary cholesterol reduces LDL-C.
Strength of Evidence: Insufﬁcient
ES indicates evidence statement; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; and SFA,
saturated fatty acid.
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intake has a beneﬁcial effect on the lipid proﬁle. Given that
reducing saturated fat intake lowers LDL-C regardless of
whether the saturated fat is replaced by carbohydrate,
monounsaturated fatty acids, or polyunsaturated fatty acids,
the Work Group does not specify which of these 3 mac-
ronutrients should be substituted in place of saturated fat.
However, favorable effects on lipid proﬁles are greater
when saturated fat is replaced by polyunsaturated fatty
acids, followed by monounsaturated fatty acids, and then
carbohydrates. It is important to note that there are various
types and degrees of reﬁnement of carbohydrates. Substi-
tution of saturated fat with whole grains is preferable to
reﬁned carbohydrates. For American adults who eat more
saturated fat than the current average, some reduction is
warranted, and adhering to a “heart-healthy” dietary
pattern from dietary recommendation No. 1 for LDL-C
lowering will likely result in a reduction of saturated fat.4. Advise adults who would beneﬁt from LDL-C
lowering to:
 Reduce percentage of calories from trans fat.
NHLBI Grade: A (strong); ACC/AHA COR: I, LOE: A
Rationale: Reducing intake of trans fatty acids lowers
LDL-C, with little or no effect on HDL-C or triglycerides
levels. The direction of the relationship between trans fatty
acids and LDL-C is consistent, regardless of whether the
trans fatty acids are replaced by carbohydrates, mono-
unsaturated fatty acids, or polyunsaturated fatty acids. Using
2003 to 2006 NHANES (National Health and Nutrition
Examination Survey) data, intake of trans fat from partially
hydrogenated oils was estimated at a mean of 1.3 g/d to 1.6
g/d among the U.S. population 2 years of age (52).
Although the intake level appears low, certain subgroups
within the U.S. population may still be consuming relatively
high levels of trans fatty acids. For this reason, the Work
Table 11. Resources and Information for Dietary Planning
DASH Eating Plan
 Your Guide to Lowering Your Blood Pressure With DASH
(http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/new_dash.pdf)
 Your Guide to Lowering Your Blood Pressure With DASH Brochure
(http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/dash_brief.pdf)
AHA Diet and Lifestyle Recommendations
 AHA Diet and Lifestyle Recommendations Article
(http://www.heart.org/HEARTORG/GettingHealthy/Diet-and-Lifestyle-Recom
mendations_UCM_305855_Article.jsp)
 AHA Diet and Lifestyle Recommendations 2006 Scientiﬁc Statement
(http://circ.ahajournals.org/content/114/1/82.full.pdf) (11)
Dietary Guidelines for Americans
 2010 Dietary Guidelines for Americans
(http://www.cnpp.usda.gov/DGAs2010-PolicyDocument.htm) (49)
 2011 Dietary Guidelines for Americans Brochure
(http://www.cnpp.usda.gov/Publications/MyPlate/DG2010Brochure.pdf)
 USDA Food Patterns
(http://www.cnpp.usda.gov/Publications/USDAFoodPatterns/USDAFoodPa
tternsSummaryTable.pdf)
AHA indicates American Heart Association; DASH, Dietary Approaches to Stop Hypertension;
and USDA, U.S. Department of Agriculture.
Table 12. CQ for Sodium and Potassium:
BP and CVD Outcomes
CQ2:
Among adults, what is the effect of dietary intake of sodium and potassium on
CVD risk factors and outcomes, when compared with no treatment or with
other types of interventions?
BP indicates blood pressure; CQ, critical question; and CVD, cardiovascular disease.
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the reduction of trans fat in the diet. Even if intake of trans
fat from partially hydrogenated oils decreases, naturally
occurring trans fatty acids in the form of ruminant fat from
meat and dairy products may still be present in small
amounts in the U.S. diet. Adhering to the recommendation
to reduce dietary sources of saturated fat (meat and dairy fat)
will result in additional reductions in trans fat intake.
4. CQ2dSodium and Potassium:
BP and CVD Outcomes
See Table 12 for the CQ on BP and CVD outcomes with
sodium and potassium.
4.1. Introduction and Rationale
Vitamins and minerals typically are consumed in foods.
However, it is sometimes possible to isolate the effect of
individual minerals to determine the effects on health
outcomes. Therefore, the Work Group decided that a
systematic review was warranted to determine the indi-
vidual effects of the minerals sodium and potassium, which
are associated with CVD risk factors and outcomes. Other
minerals, such as calcium and magnesium, were also
considered but were not included in the systematic review
because their consumption is limited to relatively few
speciﬁc foods or food groups (e.g., calcium and dairy
products); furthermore, it was unlikely that a recommen-
dation to increase or decrease consumption of the mineral
rather than the food could be implemented.
In contrast, sodium was reviewed as a single nutrient
because little sodium is found naturally in food, and it is
added to foods primarily during preparation, at preserva-
tion, and/or at the time of consumption. Therefore, it is
theoretically possible to alter sodium intake withoutaltering intake of speciﬁc foods or overall dietary pattern.
In addition, potassium was reviewed as a single nutrient
because it has been hypothesized that dietary potassium
intake may lower BP independent of other nutrients or
foods. In addition, the effect of sodium on BP may be
modulated by concomitant potassium intake.
Most of the clinical trial evidence pertains to effects of
minerals on risk factors (i.e., BP and plasma lipids) that are
relevant, intermediate outcomes for CVD. In addition,
data primarily from observational studies provide evidence
on the effects of dietary sodium and potassium on out-
comes that are CVD events.4.2. Selection of Inclusion/Exclusion Criteria
Work Group members developed eligibility criteria on the
basis of a PICOTS approach for screening potential
studies for inclusion in the evidence review. The PICOTS
approach for CQ2 and other detailed methods are in the
NHLBI Lifestyle Systematic Evidence Review report.
CQ2 was established to examine studies that assessed
the impact of sodium and potassium on BP and cardio-
vascular morbidity and mortality. The studies included
adults with or without established CVD; with or without
CVD risk factors; with or without tobacco use; and who
were of normal weight, overweight, or obese. In addition,
intervention sample sizes were required to be at least 50 for
biomarker and risk factor studies and 500 for cardiovas-
cular morbidity and mortality. Because a separate Obesity
Expert Panel reviewed evidence on the effect of weight loss
on CVD risk factors and outcomes, the Work Group
excluded studies in which weight change was >3%.4.3. Literature Search Yield
In all, 34 studies (46 citations) satisﬁed the CQ2 inclusion
criteria and were rated as good or fair quality
(31,32,46,47,53–94).
The CQ2 summary tables are available in the Full Work
Group Report supplement. The tables present data on the
studies used in the evidence review organized by mineral
(sodium or potassium), outcomes (BP or CVD outcomes),
sodium subquestions (overall results, different levels of
sodium, sodium and other dietary changes), and sub-
populations (sex, Summary Table C–4a; race/ethnicity,
Summary Table C–4b; age, Summary Table C–4c; and
hypertension status, Summary Table C–4d). Some studies
appear in more than 1 summary table because they address
more than 1 corresponding mineral or subquestion.
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See Table 13 for the CQ2 ESs for sodium and BP.
4.4.1. Sodium and BP
A note about the unit of measure presented for dietary
and urinary sodium: sodium is presented in studies in
millimoles (mmol), grams (g), and milligrams (mg). The
Work Group chose to convert the sodium results to mil-
ligrams for the ESs, recommendations, and rationales so
that data from different studies would be displayed in a
consistent unit. Also, U.S. dietary recommendations and
the Nutrition Facts labels on food products display sodium
in milligrams, and this unit (mg) will be easier for
healthcare providers to communicate with patients. Uri-
nary and dietary sodium are portrayed in the original units
from each published study in the CQ2 summary tables
(C–1 to C–8).
4.5. Diet Recommendations for BP Lowering
1. Advise adults who would beneﬁt fromBP lowering to:
a. Consume a dietary pattern that emphasizes intake
of vegetables, fruits, and whole grains; includes
low-fat dairy products, poultry, ﬁsh, legumes,
nontropical vegetable oils, and nuts; and limits
intake of sweets, sugar-sweetened beverages, and
red meats.
i. Adapt this dietary pattern to appropriate calorie
requirements, personal and cultural food pref-
erences, and nutrition therapy for other medi-
cal conditions (including diabetes).
ii. Achieve this pattern by following plans such as
the DASH dietary pattern, the USDA Food
Pattern, or the AHA Diet.NHLBI Grade: A (strong); ACC/AHA COR: I, LOE: A
Rationale: This recommendation is based largely on
studies of the DASH dietary pattern (DASH and DASH-
Sodium), which provided the highest-quality evidence that
this food-based dietary pattern improves lipid proﬁles and
BP (Tables 8 and 9, CQ1 ES3–ES9). This evidence was
supplemented by studies of low quality in which various
adaptations of the MED pattern were tested and also
found to reduce BP (Table 7, CQ1 ES1). The evidence
suggests that the effects of the recommended dietary
pattern persist as long as the pattern is consumed. The BP-
lowering effect has been demonstrated in adults with hy-
pertension and prehypertension and is evident in men and
women, African-American and non–African-American
adults, and older and younger adults (Table 8, ES5). The
dietary pattern’s effect on BP is independent of changes in
weight and sodium intake. The magnitude of effect is
sufﬁcient to prevent progression from prehypertension to
hypertension, promote nonpharmacological BP control in
those with hypertension, and supplement pharmacological
BP lowering.The caloric (energy) intake should be appropriate for the
individual (e.g., restricted for those attempting weight
loss). Patients should also be encouraged to adapt the
recommended dietary pattern to their personal and cultural
preferences. Materials are available to assist patients in
achieving the recommended dietary pattern at different
calorie levels (Table 9). The 2010 U.S. Department of
Health and Human Services Dietary Guidelines for
Americans recommend the USDA Food Pattern and the
DASH dietary pattern (49). Overall, the recommended
dietary pattern is consistent with the AHA Diet (50) and
the USDA Food Pattern (49). The USDA Food Pattern
offers lacto-ovo vegetarian and vegan adaptations. There-
fore, this recommendation is consistent with other national
guidelines. Clinicians should be familiar with the recom-
mendations, advise their patients to adopt them, and
provide easy access to information (Table 11). Dietary
planning and nutritional counseling are often facilitated by
referral to a nutrition professional.
2. Advise adults who would beneﬁt from BP
lowering to:
a. Lower sodium intakeNHLBI Grade: A (strong); ACC/AHA COR: I, LOE: A
Rationale: There is strong and consistent clinical trial
evidence that reducing sodium intake lowers BP. This BP-
lowering effect has been demonstrated in adults with hy-
pertension and prehypertension, in men and women, in
African-American and non–African-American adults, and
in older and younger adults. Trials contributing to this
evidence include well-controlled feeding studies as well as
studies in which participants were counseled to lower so-
dium intake. The effect of reducing sodium intake on BP is
independent of changes in weight. The magnitude of effect
is sufﬁcient both to prevent progression from pre-
hypertension to hypertension and to promote non-
pharmacological BP control in those with hypertension.
Observational data also suggest that lower sodium intake is
associated with lower risk of cardiovascular events in people
with and without hypertension, which is hypothesized to
occur through reductions in BP.
3. Advise adults who would beneﬁt from BP
lowering to:
a. Consume no more than 2,400 mg of sodium/d;
b. Further reductionof sodium intake to 1,500mg/d
can result in even greater reduction in BP;
c. Even without achieving these goals, reducing
sodium intake by at least 1,000 mg/d lowers BP.NHLBI Grade: B (moderate); ACC/AHA COR: IIa, LOE: B
Rationale: One well-conducted trial demonstrated clini-
cally meaningful lowering of BP when sodium was reduced
to 2,400 mg/d, with lower BPs achieved when sodium intake
was reduced to 1,500 mg/d. Reductions of 1,000 mg/d were
shown to be beneﬁcial in trials, and observational studies
Table 13. CQ2 ESs for Sodium and BP
Overall Results of Sodium and the Effect on BP:
What Is the Overall Effect of Dietary Intake of Sodium on BP?
ES1.
 In adults 25 to 80 years of age with BP 120–159/80–95 mm Hg, reducing sodium intake lowers BP.
Strength of Evidence: High
Comparison of Different Levels of Sodium Intake:
What Is the Effect of Different Levels of Dietary Sodium Intake on BP?
ES2.
 In adults 25 to 75 years of age with BP 120–159/80–95 mm Hg, a reduction in sodium intake that achieves a mean 24-h urinary sodium excretion of
approximately 2,400 mg/d, relative to approximately 3,300 mg/d, lowers BP by 2/1 mm Hg. A reduction in sodium intake that achieves a mean 24-h
urinary sodium excretion of approximately 1,500 mg/d lowers BP by 7/3 mm Hg.
Strength of Evidence: Moderate
ES3.
 In adults 30–80 years of age with or without hypertension, counseling to reduce sodium intake by an average of 1,150 mg/d reduces BP by 3–4/1–2 mm Hg.
Strength of Evidence: High
Sodium in Subpopulations:
What Is the Effect of Sodium on BP in Subgroups Deﬁned by Sex, Race/Ethnicity, Age, and Hypertension Status?
ES4.
 In adults with prehypertension or hypertension, reducing sodium intake lowers BP in women and men, African-American and non–African-American adults, and
older and younger adults.
Strength of Evidence: High
ES5.
 Reducing sodium intake lowers BP in adults with either prehypertension or hypertension who are eating either the typical American diet or the DASH dietary
pattern. The effect is greater in those with hypertension.
Strength of Evidence: High
Sodium and Dietary Pattern Changes:
What Is the Effect of Sodium on BP in the Context of Dietary Pattern Changes?
ES6.
 In adults 22–80 years of age with BP 120–159/80–95 mm Hg, the combination of reduced sodium intake plus eating the DASH dietary pattern lowers BP more
than reduced sodium intake alone.
Strength of Evidence: Moderate
Sodium in the Context of Other Minerals and BP:
What Is the Effect of Sodium on BP in the Context of Other Single Minerals?
ES7.
 There is insufﬁcient evidence from RCTs to determine whether reducing sodium intake plus changing dietary intake of any other single mineral (e.g., increasing
potassium, calcium, or magnesium) lowers BP more than reducing sodium intake alone.
Strength of Evidence: Insufﬁcient
Sodium and Congestive Heart Disease/CVD Outcomes:
What Is the Effect of Dietary Intake of Sodium on CVD Outcomes?
ES8.
 A reduction in sodium intake of approximately 1,000 mg/d reduces CVD events by about 30%.
Strength of Evidence: Low
ES9.
 Higher dietary sodium intake is associated with a greater risk of fatal and nonfatal stroke and CVD.
Strength of Evidence: Low
ES10.
 There is insufﬁcient evidence to determine the association between sodium intake and the development of HF.
Strength of Evidence: Insufﬁcient
ES11.
 There is insufﬁcient evidence to assess the effect of reducing dietary sodium intake on cardiovascular outcomes in patients with existing HF.
Strength of Evidence: Insufﬁcient
Potassium and BP and Congestive Heart Disease/CVD Outcomes:
What Is the Effect of Dietary Intake of Potassium on BP and CVD Outcomes?
ES12.
 There is insufﬁcient evidence to determine whether increasing dietary potassium intake lowers BP.
Strength of Evidence: Insufﬁcient
ES13.
 In observational studies with appropriate adjustments (e.g., BP, sodium intake), higher dietary potassium intake is associated with lower stroke risk.
Strength of Evidence: Low
ES14.
 There is insufﬁcient evidence to determine whether there is an association between dietary potassium intake and congestive heart disease, HF, or cardiovascular
mortality rate.
Strength of Evidence: Insufﬁcient
BP indicates blood pressure; CVD, cardiovascular disease; DASH, Dietary Approaches to Stop Hypertension; ES, evidence statement; HF, heart failure; and RCT, randomized controlled trial.
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Table 14. CQ for Physical Activity: Lipids and BP
CQ3:
Among adults, what is the effect of physical activity on BP and lipids when
compared with no treatment or with other types of interventions?
BP indicates blood pressure and CQ, critical question.
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with changes in sodium intake of about 1,000 mg/d. This
recommendation is directed at the two thirds of the U.S.
adults who have prehypertension or hypertension, for
whom reducing sodium intake can prevent or improve
control of hypertension and potentially reduce cardiovas-
cular events.
The Work Group acknowledges that the recommenda-
tion to reduce sodium intake to2,400mg/d differs slightly
from other current dietary recommendationsdspeciﬁcally,
the 2010 Dietary Guidelines for Americans and the
Institute of Medicine Dietary Reference Intakes; both
of these publications recommend 2,300 mg/d as the
upper limit of intake for adults. Although the impact
on behavior of a difference between intakes of 2,400
mg of sodium/d versus 2,300 mg of sodium/d would be
minimal, these recommendations are based on the
strongest clinical trial evidence available: the achieved
level of 2,400 mg/d from the DASH-Sodium trial
(estimated from average urinary sodium excretion)
(Table 11, CQ2 ES2).
The strength of this recommendation is graded “mod-
erate” because fewer clinical trials were used to devise the
2,400-mg and 1,500-mg goals than the large number of
trials used to inform the overall recommendation on so-
dium (dietary recommendation No. 2 for BP lowering),
which is graded “strong.”
Reducing sodium intake can be challenging for an in-
dividual because of the ubiquitous nature of sodium in the
American food supply. Educational materials with strate-
gies to help patients lower sodium intake are provided by
several federal and private sources (49,95–98). Ultimately,
however, signiﬁcant changes in sodium intake among U.S.
adults may require changes both in individual behavior and
in food manufacturing and processing.
4. Advise adults who would beneﬁt from BP
lowering to:
a. Combine the DASH dietary pattern with lower
sodium intake.NHLBI Grade: A (strong); ACC/AHA COR: I, LOE: A
Rationale: Both a healthy dietary pattern, as exempliﬁed
by DASH, and reduced sodium intake independently
reduce BP. However, the BP-lowering effect is even
greater when these dietary changes are combined. In the
60% of U.S. adults with prehypertension or hypertension,
simultaneously implementing dietary recommendations
No. 1 and No. 2 for BP lowering can prevent and control
hypertension more than either intervention alone.5. CQ3dPhysical Activity: Lipids and BP
See Table 14 for the CQ for physical activity and lipids
and BP.
5.1. Introduction/Rationale
Large bodies of observational data show an association
between higher levels of physical activity and lower rates of
many chronic diseases, including CVD, and enhanced
longevity (99–101). Furthermore, an inverse dose-response
relation exists, with increasing higher levels of activity
associated with commensurately lower rates of CVD in a
curvilinear fashion (102,103). In a recent analysis, it was
estimated that by eliminating physical inactivity, 6% of
coronary heart disease worldwide may be eliminated, and
life expectancy of the world population may be increased by
0.68 years (104,105).
Among the mechanisms proposed to mediate the rela-
tionship between physical activity and decreased CVD
rates are beneﬁcial effects of exercise on lipid proﬁle and
BP (106). In one study, it was estimated that the beneﬁcial
effects of physical activity on BP and development of hy-
pertension explained some 27% of the activity-related
reduction in observed CVD rates, while 19% and 16% of
the reduction in CVD rates could be explained by the
beneﬁcial effects of physical activity on traditional lipids
and novel lipids, respectively.
In the remainder of Section 5, the Work Group elab-
orates on ﬁndings from meta-analyses of the effects of
physical activity on changes in lipid proﬁle and BP.
5.2. Selection of Inclusion/Exclusion Criteria
Because of resource limitations, the Work Group included
only systematic reviews and meta-analyses of RCTs or
controlled clinical trials published from 2001 through
2011. Detailed inclusion/exclusion criteria are available in
the Full Work Group Report supplement.
5.3. Literature Search Yield
A total of 26 systematic reviews and meta-analyses were
identiﬁed that met inclusion/exclusion criteria and were
rated as good or fair quality (105,107–130).
The CQ3 subcommittee members next identiﬁed the
included systematic reviews and meta-analyses that con-
tained detailed data on BP outcomes. They identiﬁed 11
studies with data on BP outcomes. Ten meta-analyses and
1 systematic review examined the effects of aerobic exer-
cise. One systematic review looked at the effects of resis-
tance training. The CQ3 subcommittee members next
identiﬁed the included systematic reviews and meta-
analyses that contained detailed data on lipid outcomes.
They identiﬁed 14 studies with data on lipid outcomes,
including 10 meta-analyses and 4 systematic reviews.
The next step in the evidence review process for sys-
tematic reviews and meta-analyses was to develop ESs and
Table 16. ES for Aerobic Exercise Training and BP
ES1.
 Among adult men and women at all BP levels, including individuals with
hypertension, aerobic physical activity decreases systolic and diastolic BP,
on average by 2–5 mm Hg and 1–4 mm Hg, respectively. Typical in-
terventions shown to be effective for lowering BP include aerobic physical
activity of, on average, at least 12 wk duration, with 3–4 sessions per wk,
lasting on average 40 min/session and involving moderate- to vigorous-
intensity physical activity.
Strength of Evidence: High
BP indicates blood pressure and ES, evidence statement.
Table 15. ESs for Physical Activity and Lipids
Aerobic Exercise Training and Lipids
ES1.
 Among adults, aerobic physical activity, compared with control in-
terventions, reduces LDL-C 3–6 mg/dL on average.
Strength of Evidence: Moderate
ES2.
 Among adults, aerobic physical activity alone, compared with control in-
terventions, reduces non–HDL-C 6 mg/dL on average.
Strength of Evidence: Moderate
ES3.
 Among adults, aerobic physical activity alone, compared with control in-
terventions, has no consistent effect on triglycerides.
Strength of Evidence: Moderate
ES4.
 Among adults, aerobic physical activity alone, compared with control in-
terventions, has no consistent effect on HDL-C.
Strength of Evidence: Moderate
Resistance Exercise Training and Lipids
ES5.
 Among adults, resistance training, compared with control interventions,
reduces LDL-C, triglycerides, and non–HDL-C by 6–9 mg/dL on average
and has no effect on HDL-C. Typical interventions shown to reduce LDL-C,
triglycerides, and non–HDL-C and to have no effect on HDL-C include
resistance physical activity programs that average 24 wk duration and
include 3 d/wk, with 9 exercises performed for 3 sets and 11 repetitions
at an average intensity of 70% of 1 maximal repetition.
Strength of Evidence: Low
ES indicates evidence statement; HDL-C, high-density lipoprotein cholesterol; and LDL-C, low-
density lipoprotein cholesterol.
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them to the full Work Group for consideration and voting.
Because each of these systematic reviews and meta-analyses
summarizes evidence from several studies, NHLBI staff
and Work Group members determined that the develop-
ment of formal evidence tables and summary tables of
individual articles was unnecessary. CQ3 subcommittee
members developed evidence tables that are available
in the Full Work Group Report supplement (CQ3
Summary Tables: Summary Table D–1: Aerobic Exercise
and LDL-C, Summary Table D–2: Resistance Exercise
and LDL-C, Summary Table D–3: Aerobic Exercise and
HDL-C, and Summary Table D–4: Resistance Exercise
and HDL-C) to summarize the evidence on physical ac-
tivity and lipids.
5.4. CQ3 Evidence Statements
5.4.1. Physical Activity and Lipids
See Table 15 for the CQ3 ESs for physical activity and
lipids.
This section examines evidence supporting the use of
physical activity alone (i.e., not in combination with other
interventions, such as dietary interventions or weight loss)
versus no physical activity or other type of intervention for
improvements in selected blood lipids (HDL-C, LDL-C,
triglycerides, and non–HDL-C). The 2008 Physical Ac-
tivity Guidelines Advisory Committee Report was used as the
starting point for evidence review (99). Additionally, a
systematic search identiﬁed 8 meta-analyses from 2001
onward and 5 systematic reviews rated fair to good that
addressed this question and were included as the evidence
base.
5.4.2. Physical Activity and BP
This section examines evidence supporting the use of
physical activity alone (i.e., not in combination with other
interventions, such as dietary interventions or weight loss)
versus no physical activity or other types of intervention
for BP reduction. The 2008 Physical Activity Guidelines
Advisory Committee Report was used as the starting point
for evidence review (99). Additionally, a systematic search
identiﬁed 15 meta-analyses from 2001 onward and reviews
rated fair to good that addressed this question. Details of
the search are provided in the Full Work Group Report
supplement.
5.4.2.1. AEROBIC EXERCISE TRAINING AND BP
See Table 16 for the ES for aerobic exercise training
and BP.
5.4.2.2. RESISTANCE EXERCISE TRAINING AND BP
The 2008 Physical Activity Guidelines Advisory Committee
focused on data from a meta-analysis of 9 RCTs of
resistance training that included 341 subjects (131).
However, given the limited parameters of the systematic
search described previously for CQ3 (Section 5.3), only 1review was identiﬁed. A qualitative review of clinical
trialsdrandomized, nonrandomized, and uncontrolled
studiesdexamined resistance exercise training in relation
to metabolic health among patients with type 2 diabetes
(127). Ten of these studies assessed BP. Investigators
concluded that resistance exercise training resulted in
beneﬁcial changes in systolic BP, with beneﬁts in diastolic
BP observed less frequently. (The magnitude of reduction
was not speciﬁed.) Thus, the review of evidence did not
provide consistent evidence on resistance exercise training
for BP reduction.
5.4.2.3. COMBINATION OF AEROBIC AND
RESISTANCE EXERCISE TRAINING AND BP
There have been no published meta-analyses or reviews
speciﬁcally examining the effect of a combined regimen of
aerobic exercise and resistance training on BP. However, in
some of the meta-analyses and reviews described above,
Table 17. Heart-Healthy Nutrition and Physical Activity
Behaviors
Heart-Healthy Nutrition and Physical Activity Behaviors
The adult population should be encouraged to practice heart-healthy lifestyle
behaviors, including:
 Consume a dietary pattern that emphasizes intake of vegetables, fruits, and
whole grains; includes low-fat dairy products, poultry, ﬁsh, legumes,
nontropical vegetable oils, and nuts; and limits intake of sodium, sweets,
sugar-sweetened beverages, and red meats.
- Adapt this dietary pattern to appropriate calorie requirements, personal
and cultural food preferences, and nutrition therapy for other medical
conditions (including diabetes).
- Achieve this pattern by following plans such as the DASH dietary pattern,
the USDA Food Pattern, or the AHA Diet.
 Engage in 2 h and 30 min per wk of moderate-intensity physical activity, or
1 h and 15 min (75 min) per wk of vigorous-intensity aerobic physical
activity, or an equivalent combination of moderate- and vigorous-intensity
aerobic physical activity. Aerobic activity should be performed in episodes of
at least 10 min, preferably spread throughout the wk (132).
 Achieve and maintain a healthy weight. Refer to the 2013 Obesity Expert
Panel Report for recommendations on weight loss and maintenance (5).
AHA indicates American Heart Association; DASH, Dietary Approaches to Stop Hypertension;
and USDA, U.S. Department of Agriculture.
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included in pooled data related to aerobic exercise training
(113,114).
5.5. Physical Activity Recommendations
1. In general, advise adults to engage in aerobic phys-
ical activity to reduce LDL-C and non–HDL-C: 3 to
4 sessions per week, lasting on average 40 minutes
per session, and involving moderate- to vigorous-
intensity physical activity.
NHLBI Grade: B (moderate); ACC/AHA COR: IIa, LOE: A
Rationale: This recommendation was based on evidence
from meta-analyses and reviews published from 2001 on-
ward and rated fair to good. This is also consistent with the
ﬁndings of the literature review conducted for the 2008
Physical Activity Guidelines Advisory Committee Report, in
which it was found that it may require 12 metabolic
equivalent task-hours per week of exercise to favorably
inﬂuence LDL-C. The amount of physical activity rec-
ommended above for reducing LDL-C and non–HDL-C
is congruent with the amount of physical activity recom-
mended in 2008 by the federal government for overall
health: “Most health beneﬁts occur with at least 150
minutes (2 hours and 30 minutes) a week of moderate-
intensity physical activity, such as brisk walking. Addi-
tional beneﬁts occur with more physical activity” (99).
2. In general, advise adults to engage in aerobic
physical activity to lower BP: 3 to 4 sessions per
week, lasting on average 40 minutes per session,
and involving moderate- to vigorous-intensity
physical activity.
NHLBI Grade: B (moderate); ACC/AHA COR: IIa, LOE: A
Rationale: This recommendation was based on evidence
from meta-analyses and reviews rated fair to good that were
published from 2001 onward, as well as the 2008 Physical
Activity Guidelines Advisory Committee Report. The amount
of physical activity recommended above for lowering BP
is congruent with the amount of physical activity recom-
mended in 2008 by the federal government for overall
health: “Most health beneﬁts occur with at least 150
minutes (2 hours and 30 minutes) a week of moderate-
intensity physical activity, such as brisk walking. Addi-
tional beneﬁts occur with more physical activity” (99). It is
worth noting that the present recommendation is congruent
with (i.e., expends approximately the same amount of en-
ergy) but not identical to the 2008 federal guidelines. This is
because the present recommendation is based on a review of
meta-analyses of exercise in relation to BP only (hence, the
speciﬁc regimens as used in the clinical trials), whereas the
2008 federal guidelines targeted overall health (i.e., not just
BP). Additionally, the 2008 federal guidelines for overall
health make it clear that any amount of physical activity is
healthful (“Some physical activity is better than none”), andthat there is a dose-response relationship (“For most health
outcomes, additional beneﬁts occur as the amount of
physical activity increases through higher intensity, greater
frequency, and/or longer duration”).
5.6. Heart-Healthy Nutrition and
Physical Activity Behaviors
See Table 17 for information on heart-healthy nutrition
and physical activity behaviors.
Overall, the Work Group encourages heart-healthy
nutrition and physical activity behaviors for the entire
U.S. adult population as stated in the 2010 Dietary
Guidelines for Americans and the 2008 Physical Activity
Guidelines for Americans. The recommendations in
Table 17 are a consensus of the Work Group, not a
guideline, and are generally consistent with the 2010 Di-
etary Guidelines for Americans and the 2008 Physical Activity
Guidelines for Americans.
6. Gaps in Evidence and
Future Research Needs
6.1. Diet
The extensive work of the Work Group served an addi-
tional purpose, and that was to identify important gaps in
the knowledge of how lifestyle impacts CVD risk reduc-
tion. Additional research is needed on the following topics
related to diet:
 Interaction between dietary modiﬁcation and statin
treatment.
 Relative effects of saturated fats, monounsaturated
fatty acids, polyunsaturated fatty acids, trans fatty
acids, omega-3 fatty acids, and types of carbohydrates
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newer potential CVD risk factors.
 Relative effects of naturally occurring ﬁber (cereal
[whole grains] and vegetable/fruit) and supplemental
ﬁber on lipids, inﬂammation, microbiome, and other
newer potential CVD risk factors.
 Effects of dietary cholesterol on LDL-C and HDL-
C over the current ranges of cholesterol and saturated
fat intakes (5th and 95th percentiles).
 Effects of minerals in combination (other than so-
dium) on BP.
 High-density lipoprotein function in studies that
modify HDL-C by changes in diet.
 Is the minimal effect of dietary carbohydrate on
plasma triglycerides harmful?
 The effect of sodium reduction in patients with
diabetes, heart failure, and chronic kidney disease.
 Effect of dietary pattern and sodium intake in adults
taking BP-lowering or lipid-lowering medications
(e.g., effects on BP/lipids, achieving BP/lipid goals,
medication needs/costs, outcomes).
 Effect of dietary pattern and sodium intake in adults
with CVD (e.g., after myocardial infarction; after
stroke; with coronary artery disease, heart failure, or
chronic kidney disease).
 Strategies for effectively (and cost-effectively)
implementing these evidence-based recommenda-
tions. (How can primary care providers, health sys-
tems, public health agencies, local and federal
government, community organizations, and other
stakeholders help patients adopt these diet and so-
dium intake recommendations?)
 Increased understanding of racial/ethnic/socioeco-
nomic factors that may inﬂuence (a) effect of dietary
pattern and sodium on BP and lipids, (b) adoption of
diet/sodium recommendations, and (c) method of
diet assessment.
6.2. Physical Activity
Additional research is needed on the following topics
related to physical activity:
 Improved understanding of whether exercise per-
formed at a lower intensity or dose, or different
modes of exercise, can impact these outcomes.
 Further understanding the characteristics of in-
dividuals for whom exercise of a certain dose or in-
tensity can reduce LDL-C and non–HDL-C.
 Understand the source of the inconsistent ﬁndings to
better understand under what conditions exercise can
increase HDL-C or decrease triglycerides.
 Deﬁne the optimal dose of exercise that will result in
the desired changes in lipids and lipoproteins and
whether exercise performed at a lower intensity or
dose, or different modes of exercise, can impact these
outcomes. Further understand the characteristics of individuals
for whom exercise of a certain dose, intensity, or
mode can increase HDL-C or reduce triglycerides.
 Clarify the shape of the dose-response curve between
physical activity and BP.
 Expand the limited data on whether resistance ex-
ercise training lowers BP and whether a combination
of aerobic and resistance exercise training offers any
added BP lowering, compared with aerobic exercise
only.
 Determine how diet and physical activity behave
synergistically with regard to lipids and BP.
 Determine the effect of physical activity in adults
taking BP-lowering and/or lipid-lowering medica-
tions (e.g., effects on BP/lipids, achieving BP/lipid
goals, medication needs/costs, outcomes).
 Determine the effect of physical activity in adults
with CVD (e.g., after myocardial infarction; after
stroke; with coronary artery disease, heart failure, or
chronic kidney disease).
 Determine strategies for effectively (and cost-
effectively) implementing these evidence-based rec-
ommendations. (How can primary care providers,
health systems, public health agencies, local and
federal government, community organizations, and
other stakeholders help patients adopt these physical
activity recommendations?)
 Increase understanding of racial/ethnic/socioeco-
nomic factors that may inﬂuence (a) effect of physical
activity on BP and lipids and (b) adoption of physical
activity recommendations.Presidents and Staff
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